NEWS

Virax Biolabs’ Q3 2026 Investor Presentation: Next-Generation Diagnostics for Chronic Inflammation and Immune Dysfunction

The Virax Biolabs updated investor presentation for Q3 2026 has just been released. This deck provides an overview of our current clinical milestones and strategic roadmap for the coming months.
 
You can review the full presentation below or download a copy for your records:

Content feed

Related News

Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China

Virax Biolabs’ CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics